Would you consider initiation of bevacizumab maintenance in a patient with primary ovarian cancer after optimal debulking surgery and standard carbo/taxol if they did not receive bevacizumab beginning with the carbo/taxol?  

This is a complicated question. Dr. Burger presented the final results of GOG 218 at ASCO in 2018; there was no OS benefit for the addition of avastin in the upfront setting. Despite this presentation, the FDA awarded avastin approval in this setting at around the same time; a seeming contradiction....